CEFO Co.,Ltd
- Biotech or pharma, therapeutic R&D
- CMO, CRO
CEFO is clinical-stage biotech specialized in next generation cell therapies for incurable musculoskeletal diseases, with a focus on bone regeneration through its innovative differentiation platform technology. Our cell therapies are allogenic, immune-tolerant, mass-producible and stored as frozen vials thanks to advanced process innovation. CEFO’s flagship product, CF-M801, an allogenic pre-osteoblast therapy designed to treat OsteoNecrosis of the Femoral Head (ONFH, ODD designation in Korea, and in EU, EU/3/24/3022) and other severe bone conditions (fracture and spinal fusion). Following this, CF-M802, an allogenic chondrocyte therapy, is being developed to address cartilage repair. With the global population rapidly aging, CEFO is poised to revolutionize the treatment of bone-related diseases.
)
)
)
)
){kind=logo}
){kind=logo}
)
){kind=logo}
)
){kind=logo}
){kind=logo}